-
Media Release
Novartis announces five-year data that reinforce the safety and efficacy profile of Aimovig® (erenumab-aooe) in adult patients with episodic migraine
-
Media Release
Novartis US Foundation commits $25M to improve health equity by reducing health disparities in the US
-
Media Release
Novartis presents data at ACTRIMS-ECTRIMS for Kesimpta® (ofatumumab) in newly diagnosed treatment-naïve adults with relapsing multiple sclerosis
-
Media Release
Novartis new analysis shows high consistency in lowering LDL-C in individual response with investigational inclisiran
-
Media Release
Novartis launches PsO in the Know podcast series hosted by music icon Cyndi Lauper
-
Media Release
FDA approves Novartis Kesimpta® (ofatumumab), the first and only self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis
-
Media Release
Novartis announces FDA filing acceptance of Xolair® (omalizumab) prefilled syringe for self-administration across all indications
-
Media Release
Novartis announces NEJM publication of Phase III ASCLEPIOS trials demonstrating superior efficacy of ofatumumab in patients with relapsing multiple sclerosis
-
Media Release
Novartis Cosentyx receives FDA approval for new indication to treat active non-radiographic axial spondyloarthritis
-
Media Release
Novartis announces long-term, relapse-free survival benefit for high-risk, stage III melanoma patients treated with Tafinlar® + Mekinist® following surgery
-
Media Release
Novartis announces new late-breaking ofatumumab data at EAN underscoring commitment to advancing treatment of relapsing forms of multiple sclerosis (RMS)
-
Media Release
Novartis Kisqali® shows overall survival benefit in HR+/HER2- advanced breast cancer with consistent findings in patients with more aggressive disease